ArticleCancer2017
Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry.
Article in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 9 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Mechanism of action of genistein on breast cancer and differential effects of different age stages.Pharmaceutical biology · 2025Pooled it
- Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies.JNCI cancer spectrum · 2024Pooled it
- Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- Plant-Based Diets and Cancer Prognosis: a Review of Recent Research.Current nutrition reports · 2022Pooled it
- Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials.Nutrition reviews · 2020Pooled it
- Soy and isoflavones consumption and breast cancer survival and recurrence: a systematic review and meta-analysis.European journal of nutrition · 2019Pooled it
- Pooled it
- Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- Soy Isoflavones and Breast Cancer Risk: A Meta-analysis.In vivo (Athens, Greece)Pooled it
- The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.BMC urology · 2024Trial
- Soy isoflavones decrease fibroglandular breast tissue measured by magnetic resonance imaging in premenopausal women: A 2-year randomized double-blind placebo controlled clinical trial.Clinical nutrition ESPEN · 2022Trial
- Flavonoids and semi-synthetic derivatives targeting oncogenic inflammation: dose-response relationships, toxicological profiles, and synergistic potential.Inflammopharmacology · 2026Review
- The Role of Plant-Based Diets for Cancer Survivors and Planetary Health.Current oncology (Toronto, Ont.) · 2026Review
- Association Between EGFR Expression in Non-Small Cell Lung Cancer and Dietary Legume Intake.Current drug targets · 2026Article
- Formononetin: pharmacological properties and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Coumarin Derivatives as Anticancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer.Molecules (Basel, Switzerland) · 2025Review
- Review
- Review
- A Review of the Clinical and Epidemiologic Evidence Relevant to the Impact of Postdiagnosis Isoflavone Intake on Breast Cancer Outcomes.Current nutrition reports · 2025Review
- Dietary isoflavone intake among breast cancer survivors and cancer-free women.Nutrition research and practice · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundSoy foods possess both antiestrogenic and estrogen-like properties. It remains controversial whether women diagnosed with breast cancer should be advised to eat more or less soy foods, especially for those who receive hormone therapies as part of cancer treatment.
methodsThe association of dietary intake of isoflavone, the major phytoestrogen in soy, with all-cause mortality was examined in 6235 women with breast cancer enrolled in the Breast Cancer Family Registry. Dietary intake was assessed using a Food Frequency Questionnaire developed for the Hawaii-Los Angeles Multiethnic Cohort among 5178 women who reported prediagnosis diet and 1664 women who reported postdiagnosis diet. Cox proportional-hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).
resultsDuring a median follow-up of 113 months (approximately 9.4 years), 1224 deaths were documented. A 21% decrease was observed in all-cause mortality for women who had the highest versus lowest quartile of dietary isoflavone intake (≥1.5 vs < 0.3 mg daily: HR, 0.79; 95% confidence interval CI, 0.64-0.97; P
conclusionsIn this large, ethnically diverse cohort of women with breast cancer living in North America, a higher dietary intake of isoflavone was associated with reduced all-cause mortality. Cancer 2017;123:2070-2079. © 2017 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.